Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

AGM Statement

23 Oct 2008 14:25

RNS Number : 5547G
Marchpole Holdings PLC
23 October 2008
 



23 October 2008

Marchpole Holdings plc

("Marchpole" or "the Company")

Annual General Meeting Statement

At Marchpole Holdings Annual General Meeting held this morning the Chairman of Marchpole Holdings plc, Christopher Phillips, gave the following statement and update on current trading.

"At the time of the announcement on 5 August 2008 of our results for the 53 weeks ended 5 April 2008 we reported that the year to date had proved to be challenging, with very difficult trading conditions leading to a substantial loss for the full year. However, it has also been a year of significant change and some progress for the Group, as we continue to evolve into a diversified international luxury brand management business with a globally recognised portfolio of fashion brands.

Most recently we announced a successful fund raising of £2.5 million with Atlas Design, which provides the Company with a more secure foundation from which to pursue growth opportunities as they arise. In addition we have also appointed Atlas Chairman Peter Wahlberg and Atlas CEO Allan Ladow to the Board of Marchpole as non-executive directors, and we look forward to benefiting from the additional experience that they bring to the Company.

Significantly during the current financial period we have entered into a joint venture and licensing agreement with the DKNY menswear label, under the terms of which Marchpole will source, design, produce and distribute a full range of DKNY menswear apparel throughout the world, excluding the Indian and Japanese markets. The agreement is for an initial period of seven years, with the option to extend the licence for a further seven years.

Trading conditions in the current financial year continue to be extremely difficult as a result of the deterioration in consumer markets, following the ongoing global financial crisis. 

The Board is taking all appropriate measures to deal with the current challenging economic environment and is maintaining a regular dialogue with the Company's bankers, in common with most other businesses exposed to the retail sector. In the current environment the directors continue to review all options and will provide an update on the trading performance with the interim statement in early December."

For further information please contact:

For further information, please contact :

Bell Pottinger Corporate & Financial 020 7861 3232

David Rydell / Emma Kent

Marchpole Holdings plc 020 7908 7777

Chris Phillips, Chairman

Michael MorrisExecutive Deputy Chairman 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUOUORWRRRUAA
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSExercise of Options
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.